✦ LIBER ✦

Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin: Results From 3 Large Randomized Clinical Trials

✍ Scribed by David D. Waters; Jennifer E. Ho; David A. DeMicco; Andrei Breazna; Benoit J. Arsenault; Chuan-Chuan Wun; John J. Kastelein; Helen Colhoun; Philip Barter

Book ID: 118150467
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 448 KB
Volume: 57
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2010.10.047

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical predictors and timing of New Yo

Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: Results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials

✍ Luis A. Pires; William T. Abraham; James B. Young; Katrina M. Johnson 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 187 KB

PP079-MON: New-Onset Anastomotic Leakage

PP079-MON: New-Onset Anastomotic Leakage is not Associated with Changed Preoperative Nutritional Status Induced by Concurrent Chemoradiotherapy in Patients with Esophageal Cancer: Results from a Randomized Clinical Trial

✍ Ye, W.; Lou, N.; Su, D. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 58 KB

No effect of an antiaggregant treatment

No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy results from a randomized clinical trial of 303 patients

✍ B. Lebeau; C. Chastang; J. F. Muir; J. Vincent; F. Massin; C. Fabre; Petites Cel 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 422 KB 👁 3 views

No effect of an antiaggregant treatment

No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy: Results from a randomized clinical trial of 303 patients

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Outcomes in Diabetic and Nondiabetic Pat

Outcomes in Diabetic and Nondiabetic Patients Treated With Everolimus- or Paclitaxel-Eluting Stents: Results From the SPIRIT IV Clinical Trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System)

✍ Dean J. Kereiakes; Donald E. Cutlip; Robert J. Applegate; John Wang; Manejeh Yaq 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 349 KB

Teplizumab (Anti-CD3 mAb) Treatment Pres

Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

✍ Herold, K. C.; Gitelman, S. E.; Ehlers, M. R.; Gottlieb, P. A.; Greenbaum, C. J. 📂 Article 📅 2013 🏛 American Diabetes Association 🌐 English ⚖ 932 KB